Real-World Experience with Tofacitinib in IBD at a Tertiary Center.

Roni WeisshofMaya Aharoni GolanPhilip H SossenheimerKatia El JurdiJacob E OllechJoel PekowRussel D CohenAtsushi SakurabaSushila DalalDavid T Rubin

Published in: Digestive diseases and sciences (2019)

In this cohort of patients with moderate-to-severe, anti-TNF resistant IBD, tofacitinib induced clinical response in 69% of the patients. 27% were in clinical, steroid-free remission by 1 year of treatment. Tofacitinib is an effective therapeutic option for this challenging patient population.

Keyphrases

ulcerative colitis
rheumatoid arthritis
end stage renal disease
disease activity
newly diagnosed
ejection fraction
chronic kidney disease
early onset
drug induced
case report
systemic lupus erythematosus
smoking cessation